Rosen N - Search Results

1

Hsp90 as a therapeutic target in prostate cancer.

Solit DB, Scher HI, Rosen N. Solit DB, et al. Among authors: rosen n. Semin Oncol. 2003 Oct;30(5):709-16. doi: 10.1016/s0093-7754(03)00346-4. Semin Oncol. 2003. PMID: 14571418 Review.

2

Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90.

Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, Hartl FU. Schneider C, et al. Among authors: rosen n. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14536-41. doi: 10.1073/pnas.93.25.14536. Proc Natl Acad Sci U S A. 1996. PMID: 8962087 Free PMC article.

3

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.

Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn J, Scher HI. Slovin SF, et al. Among authors: rosen n. Semin Oncol. 1996 Dec;23(6 Suppl 14):41-8. Semin Oncol. 1996. PMID: 8996585 Review.

4

Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway.

Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Muise-Helmericks RC, et al. Among authors: rosen n. J Biol Chem. 1998 Nov 6;273(45):29864-72. doi: 10.1074/jbc.273.45.29864. J Biol Chem. 1998. PMID: 9792703 Free article.

5

Synthesis and evaluation of geldanamycin-estradiol hybrids.

Kuduk SD, Zheng FF, Sepp-Lorenzino L, Rosen N, Danishefsky SJ. Kuduk SD, et al. Among authors: rosen n. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. doi: 10.1016/s0960-894x(99)00185-7. Bioorg Med Chem Lett. 1999. PMID: 10340605

6

Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.

Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Zheng FF, et al. Among authors: rosen n. Cancer Res. 2000 Apr 15;60(8):2090-4. Cancer Res. 2000. PMID: 10786665

7

Synthesis and evaluation of geldanamycin-testosterone hybrids.

Kuduk SD, Harris TC, Zheng FF, Sepp-Lorenzino L, Ouerfelli Q, Rosen N, Danishefsky SJ. Kuduk SD, et al. Among authors: rosen n. Bioorg Med Chem Lett. 2000 Jun 5;10(11):1303-6. doi: 10.1016/s0960-894x(00)00208-0. Bioorg Med Chem Lett. 2000. PMID: 10866406

8

A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility.

Sirotnak FM, Sepp-Lorenzino L, Kohl NE, Rosen N, Scher HI. Sirotnak FM, et al. Among authors: rosen n. Cancer Chemother Pharmacol. 2000;46(1):79-83. doi: 10.1007/s002800000126. Cancer Chemother Pharmacol. 2000. PMID: 10912583

9

Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

Srethapakdi M, Liu F, Tavorath R, Rosen N. Srethapakdi M, et al. Among authors: rosen n. Cancer Res. 2000 Jul 15;60(14):3940-6. Cancer Res. 2000. PMID: 10919672

10

A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. Chiosis G, et al. Among authors: rosen n. Chem Biol. 2001 Mar;8(3):289-99. doi: 10.1016/s1074-5521(01)00015-1. Chem Biol. 2001. PMID: 11306353

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

723 results

Search Page